EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial

Philip Leissner iD, Katarina Mars iD, Sophia Humphries iD, Patric Karlström iD, Troels Yndigegn iD, Tomas Jernberg iD, Robin Hofmann iD, Claes Held iD, Erik M G Olsson iD

European Heart Journal: Acute Cardiovascular Care · 2024

DOI: 10.1093/ehjacc/zuae112 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2024. Verfasst von Philip Leissner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Uppsala University, MTC-huset, Dag Hammarskjölds väg 14B, Akademiska sjukhuset, 752 37 Uppsala, Sweden. Hauptthemen laut MEDLINE: Myocardial Infarction, Adrenergic beta-Antagonists, Quality of Life, Anxiety. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Heart and Lung Association, Swedish Heart-Lung Foundation, Region Stockholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Among patients with myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI trial did not demonstrate a benefit of beta-blocker vs. no beta-blocker treatment on all-cause mortality and recurrent myocardial infarction. The aim of this pre-specified sub-study was to investigate effects of beta-blockers on self-reported symptoms of anxiety and depression. Methods and results In this parallel-group, open-label, registry-based randomized trial, assessments with the Hospital Anxiety and Depression Scale were obtained at hospitalization and two follow-up points (6–10 weeks and 12–14 months) after MI. Analyses were based on the intention-to-treat principle using linear mixed models, calculating both short- and long-term effects. From August 2018 through June 2022, 806 patients were enrolled. At baseline, 27% of patients were possible cases of anxiety (m, 5.6; SD, 3.9) and 14% were possible cases of depression (m, 3.9; SD, 3.2). Beta-blocker treatment had a negative effect on depressive symptoms at both follow-ups 1 (β = 0.48; 95% CI 09–0.86; P = 0.015) and 2 (β = 0.41; 95% CI = 0.01–0.81; P = 0.047), but no effect on anxiety.

Conclusion

Beta-blocker treatment led to a modest increase in depressive symptoms among MI patients with preserved LVEF. This observed effect was most pronounced in individuals with prior beta-blocker treatment. In routine initiation and continuation of beta-blocker treatment, a risk of slightly increased depressive symptoms should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionAdrenergic beta-AntagonistsQuality of LifeAnxietyDepressionVentricular Function, LeftHumansMaleFemaleMiddle AgedAgedStroke VolumeFollow-Up StudiesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

AnxietyBeta-blockerDepressionLinear mixed modelsPsychological distressTreatment

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Women's and Children's Health, Uppsala University, MTC-huset, Dag Hammarskjölds väg 14B, Akademiska sjukhuset, 752 37 Uppsala, Sweden.
  • Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.
  • Department of Neurobiology, Care Science and Society, Karolinska Institutet, Stockholm, Sweden.
  • Department of Internal Medicine, Ryhov County Hospital, Jönköping, Sweden.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.

ORCID-Profile: Philip Leissner, Katarina Mars, Sophia Humphries, Patric Karlström, Troels Yndigegn, Tomas Jernberg, Robin Hofmann, Claes Held, Erik M G Olsson

Förderung

  • Swedish Heart and Lung Association
  • Swedish Heart-Lung Foundation
  • Region Stockholm
  • Swedish Research Council to the U-CARE strategic research environment

Zitieren

APA

Leissner, P., Mars, K., Humphries, S., Karlström, P., Yndigegn, T., Jernberg, T., Hofmann, R., Held, C., & Olsson, E. M. G. (2024). Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuae112

Vancouver

Leissner P, Mars K, Humphries S, Karlström P, Yndigegn T, Jernberg T, et al. Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial. European Heart Journal: Acute Cardiovascular Care. 2024. doi:10.1093/ehjacc/zuae112

BibTeX
@article{Leissner2024,
  author = {Leissner, Philip and Mars, Katarina and Humphries, Sophia and Karlström, Patric and Yndigegn, Troels and Jernberg, Tomas and Hofmann, Robin and Held, Claes and Olsson, Erik M G},
  title = {Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2024},
  doi = {10.1093/ehjacc/zuae112}
}
Kostenlos starten →